Optimi Health Secures Health Canada Nod for Phase 3 MDMA PTSD Trial
OPTH sits 54% above its 52-week low of $3.485.
Summary
Optimi Health announced a Health Canada-authorized Phase 3 trial of MDMA-assisted therapy for PTSD, enrolling up to 100 veterans and frontline workers, with the trial expected to begin in 2027.
Key Events · Product Development and Regulatory · OPTH
-
Phase 3 MDMA Trial Authorized
Health Canada authorized a Phase 3 clinical trial of MDMA-assisted therapy for PTSD, with enrollment of up to 100 participants across multiple Canadian sites.
-
Trial Design and Endpoint
Participants will receive synthetic MDMA HCl in two dosage formats during two supervised sessions; primary endpoint is change in CAPS-5 score.
-
Enrollment Focus
Trial targets veterans and frontline workers including military, police, paramedics, firefighters, and healthcare workers.
-
Timeline
Trial expected to begin in 2027; no near-term revenue impact.
Analysis · OPTH · Life Sciences
A meaningful regulatory milestone has been reached: Health Canada has authorized a Phase 3 trial of MDMA-assisted therapy for PTSD, targeting up to 100 veterans and frontline workers across multiple Canadian sites. This expands the company's clinical pipeline beyond its recently announced Phase 2 psilocybin trial for major depressive disorder. While the trial is expected to begin in 2027, limiting near-term revenue impact, the authorization validates the company's synthetic MDMA manufacturing capabilities and positions it for potential registration submissions. Against the backdrop of a $100M equity line and a 383% potential dilution overhang disclosed in August, this clinical progress is a positive development that could support the company's valuation narrative.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.9% of the 1666 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OPTH was trading at $5.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29M. The 52-week trading range was $3.49 to $8.84. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.